SG11201703669YA - Anti-cldn chimeric antigen receptors and methods of use - Google Patents
Anti-cldn chimeric antigen receptors and methods of useInfo
- Publication number
- SG11201703669YA SG11201703669YA SG11201703669YA SG11201703669YA SG11201703669YA SG 11201703669Y A SG11201703669Y A SG 11201703669YA SG 11201703669Y A SG11201703669Y A SG 11201703669YA SG 11201703669Y A SG11201703669Y A SG 11201703669YA SG 11201703669Y A SG11201703669Y A SG 11201703669YA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- chimeric antigen
- antigen receptors
- cldn
- cldn chimeric
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2014/064165 WO2015069794A2 (en) | 2013-11-06 | 2014-11-05 | Novel anti-claudin antibodies and methods of use |
US201562157928P | 2015-05-06 | 2015-05-06 | |
US201562247108P | 2015-10-27 | 2015-10-27 | |
PCT/US2015/059106 WO2016073649A1 (en) | 2014-11-05 | 2015-11-04 | Anti-cldn chimeric antigen receptors and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201703669YA true SG11201703669YA (en) | 2017-06-29 |
Family
ID=55909771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201703669YA SG11201703669YA (en) | 2014-11-05 | 2015-11-04 | Anti-cldn chimeric antigen receptors and methods of use |
Country Status (23)
Country | Link |
---|---|
US (1) | US20170334991A1 (en) |
EP (1) | EP3215523A4 (en) |
JP (1) | JP2017535283A (en) |
KR (1) | KR20170085531A (en) |
CN (1) | CN107207580A (en) |
AU (1) | AU2015343079A1 (en) |
BR (1) | BR112017009517A2 (en) |
CA (1) | CA2966618A1 (en) |
CL (1) | CL2017001118A1 (en) |
CO (1) | CO2017005538A2 (en) |
CR (1) | CR20170235A (en) |
DO (1) | DOP2017000110A (en) |
EA (1) | EA201790967A1 (en) |
EC (1) | ECSP17031725A (en) |
IL (1) | IL252090A0 (en) |
MA (1) | MA40921A (en) |
MX (1) | MX2017005797A (en) |
PE (1) | PE20171060A1 (en) |
PH (1) | PH12017500825A1 (en) |
SG (1) | SG11201703669YA (en) |
TW (1) | TW201625677A (en) |
WO (1) | WO2016073649A1 (en) |
ZA (1) | ZA201703471B (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2011009632A (en) | 2009-03-30 | 2011-10-19 | Eisai R&D Man Co Ltd | Liposome composition. |
US10053511B2 (en) * | 2013-11-06 | 2018-08-21 | Abbvie Stemcentrx Llc | Anti-claudin antibodies and methods of use |
JP7015237B2 (en) | 2016-04-28 | 2022-02-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | How to control tumor growth |
MX2019003994A (en) * | 2016-10-14 | 2019-09-19 | Merck Sharp & Dohme | Combination of a pd-1 antagonist and eribulin for treating urothelial cancer. |
US11628223B2 (en) | 2017-09-29 | 2023-04-18 | Daiichi Sankyo Company, Limited | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines |
WO2020114518A1 (en) * | 2018-12-07 | 2020-06-11 | 科济生物医药(上海)有限公司 | Tumor combined immunotherapy |
JP2022524906A (en) * | 2019-01-07 | 2022-05-11 | クレージュ メディカル カンパニー,リミテッド | Combination of cell immunotherapy |
US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
US20210347847A1 (en) * | 2020-05-11 | 2021-11-11 | The Broad Institute, Inc. | Therapeutic targeting of malignant cells using tumor markers |
WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
CA3212530A1 (en) * | 2021-03-05 | 2022-09-09 | Shanghai GenBase Biotechnology Co., Ltd. | Anti-cldn6 antibody and use thereof |
CN114478802B (en) * | 2022-01-28 | 2023-05-26 | 郑州大学 | Chimeric antigen receptor and application thereof |
WO2024088325A1 (en) * | 2022-10-25 | 2024-05-02 | 科济生物医药(上海)有限公司 | Antibody and use thereof |
CN117169518B (en) * | 2023-11-03 | 2024-01-19 | 赛德特(北京)生物工程有限公司 | Method and kit for detecting CD3 antibody residues in T lymphocyte preparation |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101074261A (en) * | 2006-04-30 | 2007-11-21 | 北京同为时代生物技术有限公司 | TRAIL receptor I and/or TRAIL receptor 2 specific antibody and its use |
JP5374360B2 (en) * | 2007-02-27 | 2013-12-25 | 中外製薬株式会社 | Pharmaceutical composition comprising anti-GRP78 antibody as an active ingredient |
US9274119B2 (en) * | 2008-01-11 | 2016-03-01 | The University Of Tokyo | Anti-CLDN6 antibody |
RU2675997C2 (en) * | 2009-11-11 | 2018-12-25 | Ганимед Фармасьютикалз Аг | Antibodies specific to claudin 6 (cldn6) |
EP2404936A1 (en) * | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
ES2769574T3 (en) * | 2013-03-15 | 2020-06-26 | Michael C Milone | Recognition of cytotoxic cells with chimeric receptors for adoptive immunotherapy |
US10053511B2 (en) * | 2013-11-06 | 2018-08-21 | Abbvie Stemcentrx Llc | Anti-claudin antibodies and methods of use |
SI3514172T1 (en) * | 2014-04-01 | 2020-07-31 | Biontech Cell & Gene Therapies Gmbh | Claudin-6-specific immunoreceptors and t cell epitopes |
WO2016180467A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination |
TW201726175A (en) * | 2015-12-04 | 2017-08-01 | 艾伯維史坦森特瑞斯有限責任公司 | Novel anti-CLAUDIN antibodies and methods of use |
-
2015
- 2015-11-03 MA MA040921A patent/MA40921A/en unknown
- 2015-11-04 JP JP2017543306A patent/JP2017535283A/en active Pending
- 2015-11-04 MX MX2017005797A patent/MX2017005797A/en unknown
- 2015-11-04 SG SG11201703669YA patent/SG11201703669YA/en unknown
- 2015-11-04 CN CN201580072018.5A patent/CN107207580A/en active Pending
- 2015-11-04 EA EA201790967A patent/EA201790967A1/en unknown
- 2015-11-04 BR BR112017009517A patent/BR112017009517A2/en not_active Application Discontinuation
- 2015-11-04 PE PE2017000813A patent/PE20171060A1/en not_active Application Discontinuation
- 2015-11-04 WO PCT/US2015/059106 patent/WO2016073649A1/en active Application Filing
- 2015-11-04 CA CA2966618A patent/CA2966618A1/en not_active Abandoned
- 2015-11-04 EP EP15857690.0A patent/EP3215523A4/en not_active Withdrawn
- 2015-11-04 US US15/524,675 patent/US20170334991A1/en not_active Abandoned
- 2015-11-04 KR KR1020177015413A patent/KR20170085531A/en unknown
- 2015-11-04 CR CR20170235A patent/CR20170235A/en unknown
- 2015-11-04 AU AU2015343079A patent/AU2015343079A1/en not_active Abandoned
- 2015-11-05 TW TW104136552A patent/TW201625677A/en unknown
-
2017
- 2017-05-02 DO DO2017000110A patent/DOP2017000110A/en unknown
- 2017-05-03 IL IL252090A patent/IL252090A0/en unknown
- 2017-05-04 PH PH12017500825A patent/PH12017500825A1/en unknown
- 2017-05-05 CL CL2017001118A patent/CL2017001118A1/en unknown
- 2017-05-19 ZA ZA2017/03471A patent/ZA201703471B/en unknown
- 2017-05-25 EC ECIEPI201731725A patent/ECSP17031725A/en unknown
- 2017-06-02 CO CONC2017/0005538A patent/CO2017005538A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20170085531A (en) | 2017-07-24 |
PE20171060A1 (en) | 2017-07-21 |
EP3215523A1 (en) | 2017-09-13 |
AU2015343079A1 (en) | 2017-05-25 |
ZA201703471B (en) | 2019-06-26 |
JP2017535283A (en) | 2017-11-30 |
CO2017005538A2 (en) | 2017-10-10 |
BR112017009517A2 (en) | 2017-12-19 |
US20170334991A1 (en) | 2017-11-23 |
EP3215523A4 (en) | 2018-06-20 |
DOP2017000110A (en) | 2017-05-31 |
ECSP17031725A (en) | 2017-06-30 |
PH12017500825A1 (en) | 2017-10-18 |
CN107207580A (en) | 2017-09-26 |
CA2966618A1 (en) | 2016-05-12 |
IL252090A0 (en) | 2017-07-31 |
TW201625677A (en) | 2016-07-16 |
MX2017005797A (en) | 2017-10-23 |
EA201790967A1 (en) | 2017-10-31 |
WO2016073649A1 (en) | 2016-05-12 |
MA40921A (en) | 2017-09-12 |
CR20170235A (en) | 2017-07-21 |
CL2017001118A1 (en) | 2018-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL281819A (en) | Chimeric antigen receptors and methods of making | |
IL252295A0 (en) | Chimeric antigen receptors and methods of use thereof | |
HK1249405A1 (en) | Anti-dll3 chimeric antigen receptors and methods of use | |
IL255336A0 (en) | Chimeric antigen receptors and methods of their use | |
IL262041A (en) | Chimeric receptors and methods of use thereof | |
HK1243102A1 (en) | Anti-cd79b antibodies and methods of use | |
HRP20181359T1 (en) | Anti-jagged1 antibodies and methods of use | |
IL251868A0 (en) | Anti-tim3 antibodies and methods of use | |
ZA201703471B (en) | Anti-cldn chimeric antigen receptors and methods of use | |
IL252604B (en) | Chimeric antigen receptors and methods of use | |
IL251165A0 (en) | Anti-il-1beta antibodies and methods of use | |
IL251286A0 (en) | Anti-pdgf-b antibodies and methods of use | |
AU2016222891A1 (en) | Anti-DLL3 chimeric antigen receptors and methods of use |